FRESH2 GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3615 USD | -2.95% |
|
-11.89% | -59.38% |
| Mar. 21 | ADRs Edge Higher; Lufax Climbs Almost 46% | DJ |
| Mar. 19 | ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6% | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.
Calendar
2024-05-13
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -59.38% | 8.28M | |
| -13.68% | 11.86B | |
| +46.62% | 3.32B | |
| -40.26% | 2.08B | |
| -18.71% | 2.05B | |
| -31.23% | 1.45B | |
| +24.27% | 1.07B | |
| -4.80% | 723M | |
| -34.58% | 425M | |
| -43.88% | 422M |
- Stock Market
- Equities
- FRES Stock
- News Fresh2 Group Limited
- AnPac Bio-Medical Science Launches US Subsidiary; $5 Million Private Placement; Shares Fall Early
